Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 8 mechanisms across 8 industry trials with a known mechanism of action.

See full pipeline →

PCSK9 Inhibitor

1 trials 1 active 1 sponsor

Nonsteroidal Anti-inflammatory Drug

1 trials 1 sponsor

P2Y12 Platelet Inhibitor

1 trials 1 sponsor

Aldosterone Antagonist

1 trials 1 sponsor

Sodium-Glucose Cotransporter 2 Inhibitor

1 trials 1 sponsor

SGLT2

1 trials 1 sponsor

Anti-coagulant

1 trials 1 sponsor

Angiotensin Converting Enzyme Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

104 industry-sponsored trials across 78 sponsors

View full landscape →

Showing 10 of 10 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Amgen	Evolocumab	PCSK9 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-05-29	NCT05284747
Shanghai Hutchison Pharmaceuticals Limited	Aspirin	Nonsteroidal Anti-inflammatory Drug [EPC]	NOT YET RECRUITING	2028-12	NCT07153744
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.	rhTNK-tPA	—	COMPLETED	2019-10	NCT02835534
AstraZeneca	Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)	—	COMPLETED	2017-02-09	NCT02406248
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2013-11	NCT01347580
Balton Sp.zo.o.	—	—	COMPLETED	2013-09	NCT01637012
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Eplerenone	Aldosterone Antagonist [EPC]	COMPLETED	2012-10	NCT01176968
InspireMD	—	—	COMPLETED	2012-06	NCT01368471
Datascope Corp.	—	—	COMPLETED	2011-03	NCT00833612
InspireMD	—	—	WITHDRAWN	2015-11	NCT02222116

Showing 29 of 29 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novo Nordisk	Ziltivekimab	—	RECRUITING	2026-12-14	NCT06118281
ECRI bv	Ziltivekimab	—	RECRUITING	2028-09-01	NCT07276282
Novo Nordisk	Ziltivekimab	—	RECRUITING	2028-11-14	NCT07301034
CeleCor Therapeutics	zalunfiban	—	ACTIVE NOT RECRUITING	2026-05-13	NCT04825743
Faraday Pharmaceuticals, Inc.	FDY-5301	—	COMPLETED	2025-09-03	NCT04837001
Pharmicell Co., Ltd.	Hearticellgram-AMI	—	COMPLETED	2024-08-12	NCT01652209
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2023-11-05	NCT04509674
AstraZeneca	Dapagliflozin	SGLT2	COMPLETED	2023-07-05	NCT04564742
Novartis	LCZ696 (sacubitril/valsartan)	—	COMPLETED	2021-02-26	NCT02924727
AO GENERIUM	Revelise (GENERIUM, Russia)	—	COMPLETED	2017-11-21	NCT07146360
Supergene, LLC	Recombinant staphylokinase	—	COMPLETED	2016-12-01	NCT02301910
AstraZeneca	Ticagrelor 90 mg	—	COMPLETED	2014-12	NCT01225562
Abbott Diagnostics Division	—	—	COMPLETED	2014-08	NCT01608100
Angel Medical Systems	—	—	COMPLETED	2014-05-01	NCT00781118
Boehringer Ingelheim	enoxaparin	—	COMPLETED	2012-09-01	NCT00623623
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Rivaroxaban 2.5 mg	—	COMPLETED	2011-09	NCT00809965
Bharat Biotech International Limited	THR-100	—	COMPLETED	2011-08	NCT01305226
Merck	Vorapaxar 2.5 mg	—	COMPLETED	2010-10-01	NCT00617123
Sanofi	clopidogrel (SR25990)	—	COMPLETED	2010-08	NCT00821834
Dexa Medica Group	DLBS1033	—	TERMINATED	2023-01	NCT02976701
The Medicines Company	Bivalirudin	Anti-coagulant [EPC]	TERMINATED	2016-06-14	NCT02565147
Stentys	—	—	TERMINATED	2015-12	NCT01732341
Eurofarma Laboratorios S.A.	Enoxaparin	—	TERMINATED	2013-07	NCT01356992
CardioKinetix, Inc	—	—	TERMINATED	2013-01	NCT01286116
Merck	Acadesine	—	TERMINATED	2010-10	NCT00872001
Abiomed Inc.	—	—	TERMINATED	2010-08	NCT00972270
Viatris Innovation GmbH	—	—	ENROLLING BY INVITATION	2026-12	NCT04957719
Novartis	sacubitril/valsartan	—	WITHDRAWN	2023-06-01	NCT04637555
Dexa Medica Group	DLBS1033	—	WITHDRAWN	2017-11	NCT02146664

Showing 53 of 53 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Beijing Sungen Biomedical Technology Co., Ltd	SGC001	—	RECRUITING	2027-06	NCT07306182
Ever Supreme Bio Technology Co., Ltd.	Allogeneic umbilical cord mesenchymal stem cells	—	RECRUITING	2027-06-24	NCT06147986
Nyrada Pty Ltd	Xolatryp	—	RECRUITING	2027-06-30	NCT07362446
ResoTher Pharma	RTP-026	—	RECRUITING	2025-12-21	NCT06465303
Implicit Bioscience	Atibuclimab (IC14), 20 mg/kg intravenously, once	—	ACTIVE NOT RECRUITING	2026-06-01	NCT06678074
Beijing Northland Biotech. Co., Ltd.	Recombinant Human Thymosin Beta 4 Injection (NL005)	—	NOT YET RECRUITING	2027-08-17	NCT07586865
HONYA Medical Co Ltd	Cord Blood Nucleated cells	—	NOT YET RECRUITING	2027-12-31	NCT07134712
Cardior Pharmaceuticals GmbH	CDR132L	—	COMPLETED	2024-09-26	NCT05350969
CellProthera	PROTHERACYTES	—	COMPLETED	2024-03-15	NCT02669810
Beijing Northland Biotech. Co., Ltd.	NL005 Middle Dose	—	COMPLETED	2023-05-26	NCT05984134
Honya Medical Inc	MiSaver®	—	COMPLETED	2023-05-04	NCT04050163
Bayer	BAY2433334	—	COMPLETED	2022-02-21	NCT04304534
R-Pharm Overseas, Inc.	RPH-104 80 mg	—	COMPLETED	2021-11-03	NCT04463251
Beijing Northland Biotech. Co., Ltd.	Low Dose	—	COMPLETED	2021-09-30	NCT05485818
Quantum Genomics SA	Ramipril	Angiotensin Converting Enzyme Inhibitor [EPC]	COMPLETED	2021-07-08	NCT03715998
PT. Prodia Stem Cell Indonesia	Mesenchymal Stem Cells	—	COMPLETED	2021-04-08	NCT04340609
Mesoblast, Inc.	Mesenchymal Precursor Cells (MPC) 12.5 M	—	COMPLETED	2021-04-06	NCT01781390
Recardio, Inc.	Dutogliptin Tartrate	—	COMPLETED	2021-02-26	NCT03486080
MedImmune LLC	MEDI6012	—	COMPLETED	2021-01-18	NCT03578809
CeleCor Therapeutics	RUC-4 Compound	—	COMPLETED	2020-11-08	NCT04284995
Athera Biotechnologies AB	ATH3G10	—	COMPLETED	2020-07-06	NCT03991143
Medicure	Short Tirofiban	—	COMPLETED	2018-12	NCT01522417
Viatris Innovation GmbH	Selatogrel 8 mg	—	COMPLETED	2018-11-10	NCT03487445
Bayer	Fulacimstat (BAY1142524)	—	COMPLETED	2018-07-31	NCT02976467
Faraday Pharmaceuticals, Inc.	FDY-5301	—	COMPLETED	2018-07-14	NCT03470441
CSL Behring	CSL_112	—	COMPLETED	2017-06	NCT02742103
CSL Behring	CSL112	—	COMPLETED	2015-12	NCT02108262
Coretherapix	Allogeneic human cardiac stem cells (CSCs)	—	COMPLETED	2015-12	NCT02439398
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2015-10	NCT01213251
Polyphor Ltd.	POL6326	—	COMPLETED	2015-10	NCT01905475
LG Life Sciences	LC28-0126 Dose A	—	COMPLETED	2015-06	NCT02070471
Lee's Pharmaceutical Limited	Anfibatide	—	COMPLETED	2014-12	NCT01585259
Lisata Therapeutics, Inc.	NBS10	—	COMPLETED	2014-06	NCT01495364
Cytori Therapeutics	Dose A	—	COMPLETED	2014-05	NCT01216995
Egetis Therapeutics	Mangafodipir	—	COMPLETED	2013-05	NCT00966563
Roche	RO4905417	—	COMPLETED	2012-10	NCT01327183
OrbusNeich	—	—	COMPLETED	2012-08	NCT01405287
Eagle Vision Pharmaceutical Corp.	SeeMore(TM)	—	COMPLETED	2012-03	NCT00881075
Terumo Europe N.V.	—	—	COMPLETED	2011-09	NCT01271361
Mesoblast, Inc.	Prochymal®	—	COMPLETED	2011-05-18	NCT00877903
Ablynx, a Sanofi company	ALX-0081	—	COMPLETED	2011-04	NCT01020383
KAI Pharmaceuticals	KAI-9803	—	COMPLETED	2010-07	NCT00785954
Stempeutics Research Pvt Ltd	Stem cell	—	COMPLETED	2010-05	NCT00883727
Boehringer Ingelheim	BI 765845	—	TERMINATED	2025-09-02	NCT06139328
Pharming Technologies B.V.	conestat alfa or placebo	—	TERMINATED	2023-04-28	NCT04912141
Healios K.K.	AMI MultiStem cells	—	TERMINATED	2019-06	NCT02277613
Capricor Inc.	CAP-1002 Allogeneic Cardiosphere-Derived Cells	—	TERMINATED	2017-07-03	NCT01458405
Angion Biomedica Corp	BB3	—	TERMINATED	2013-07	NCT01539590
Valo Health, Inc.	OPL-0301 Dose 1	—	WITHDRAWN	2024-08	NCT05327855
RegeneRx Biopharmaceuticals, Inc.	Drug: Injectable Thymosin beta 4	—	WITHDRAWN	2020-07	NCT01311518
CellProthera	—	—	WITHDRAWN	2020-06-30	NCT04198883
Helixmith Co., Ltd.	Stage 1-Low dose VM202RY	—	WITHDRAWN	2019-08-20	NCT03404024
Stemedica Cell Technologies, Inc.	Stem cells	—	WITHDRAWN	2016-05	NCT01770613

Showing 12 of 12 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Viscofan	—	—	NOT YET RECRUITING	2026-12-31	NCT06956807
Beijing Sungen Biomedical Technology Co., Ltd	SGC001	—	COMPLETED	2025-07-18	NCT07091929
Beijing Sungen Biomedical Technology Co., Ltd	SGC001	—	COMPLETED	2025-07-15	NCT07079618
CorFlow Therapeutics AG	—	—	COMPLETED	2024-12-18	NCT03654573
Bayer	Asundexian (BAY2433334)	—	COMPLETED	2023-05-24	NCT05419635
Nexel Co., Ltd.	NP-011 (Single Ascending Dose Phase)	—	COMPLETED	2023-03-07	NCT05387499
Ever Supreme Bio Technology Co., Ltd.	Allogeneic umbilical cord mesenchymal stem cells	—	COMPLETED	2021-08-02	NCT04056819
Ventrix, Inc.	VentriGel	—	COMPLETED	2018-09-05	NCT02305602
CSL Behring	CSL112	—	COMPLETED	2015-11	NCT02427035
Healios K.K.	AMI MultiStem®	—	COMPLETED	2010-03	NCT00677222
Shanghai Life Science & Technology	UC-MSC	—	WITHDRAWN	2025-12-31	NCT03902067
RegeneRx Biopharmaceuticals, Inc.	thymosin beta 4	—	WITHDRAWN	2017-01-01	NCT00743769

Novel Drugs by Company (New molecular entities)

MEDI-PHYSICS 1 drug

MYOVIEW

TECHNETIUM TC-99M TETROFOSMIN KIT

GE HLTHCARE 1 drug

Reformulations (30 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.